Dantrolene: new indication. Cerebral palsy in children: uncertain clinical benefit.
The symptomatic efficacy of dantrolene in children is poorly documented, especially in terms of its adverse effects, mainly those affecting the liver.
D002547:Cerebral Palsy / Q000188:drug therapy*; D002648:Child; D003620:Dantrolene / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D005602:France; D006801:Humans; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009128:Muscle Spasticity / Q000188:drug therapy*
D009125:Muscle Relaxants, Central; D003620:Dantrolene